来自穿膜肽的新肽的抗菌活性及抑菌机制

[目的]研究基于穿膜肽和抗菌肽构效关系改造获得的新肽P7的抗菌活性及其对大肠杆菌(E.coli)的抑菌机制.[方法]微量稀释法和溶血实验分析P7的抑菌活性及其对正常细胞的细胞毒性;采用膜荧光探针、流式细胞术和扫描电镜分析P7对E.coli膜通透性、膜完整性的影响和细胞超微结构变化;通过激光共聚焦分析P7在E.coli细胞中的定位;凝胶阻滞实验测定P7与E.coli基因组DNA结合能力.[结果]P7比母肽显示更强的抑菌活性,最低抑菌浓度范围为4-32 μmol/L,且在作用浓度范围内具有较弱的溶血活性.P7可以增加E.coli外膜和内膜的通透性,使E.coli细胞膜的完整性和细胞表面结构受损.同时P7可以穿过E.coli细胞膜在细胞质聚集并与基因组DNA结合.[结论]P7通过增加E.coli内外膜通透性,穿过细胞膜与胞内DNA结合发挥抑菌活性.     

天蚕素A-爪蟾素2杂合肽P18对MDA-MB-435s乳腺癌细胞的作用研究

目的 研究天蚕素A-爪蟾素2杂合肽P18对体外培养的人类乳腺癌细胞株MDA-MB-435s的活性作用.方法 采用MTT法检测P18对体外培养的MDA-MB-435s细胞增殖的影响;使用Live/Dead Viability/Cytotoxicity试剂盒对细胞进行染色,并在荧光显微镜下观察细胞的存活状态;通过DiBAC_4(3)染色,以荧光分光光度计检测给肽时细胞膜的膜电位变化;在透射电子显微镜下观察P18作用24 h后细胞超微结构的变化.结果 MTT试验表明P18对MDA-MB-435s细胞的增殖具有浓度依赖性的抑制作用;荧光显微镜下可观察到P18可以使MDA-MB-435s细胞膜破损,细胞死亡;P18作用时,荧光分光光度计检测到MDA-MB-435s的细胞膜发生了去极化现象;透射电子显微镜下可见大量细胞崩解坏死.结论 杂合肽P18能够引起MDA-MB-435s细胞膜的通透性改变而导致细胞坏死.     

人参总皂苷对K562细胞促红细胞生成素受体的作用

目的:研究人参总皂苷(TSPG)对人红白血病细胞株(K562)促红细胞生成素受体(EpoR)的作用.方法:以50、100、200、300、500mg/L TSPG刺激K562细胞24h,采用流式细胞仪检测细胞膜EpoR表达的变化;Elisa检测K562细胞膜、细胞浆EpoR表达量的改变;激光共聚焦显微镜观察K562细胞EpoR表达的分布.结果:以不同剂量,TSPG作用K562细胞24h,流式细胞仪检测显示K562细胞膜表面EpoR呈剂量依赖性下降;细胞Elisa实验结果也显示K562细胞膜表面EpoR表达呈剂量依赖性下降,而细胞浆内EpoR表达呈剂量依赖性增加;激光共聚焦显微镜观察可见K562细胞经200mg/L TSPG作用24h后其膜上的EpoR数量明显减少,荧光强度明显减弱.结论:TSPG可使K562细胞浆EpoR的表达增强,且随着剂量的加大更加明显,而使细胞膜中EpoR的表达减少,这可能是,TSPG抑制K562细胞增殖的作用机制之一.     

过表达PTPα促进K562细胞体外增殖能力和体内致瘤性

探讨蛋白质酪氨酸磷酸酶α（PTPα）在血液肿瘤细胞中的特异性表达,研究过量表达PTPα对人红白血病细胞K562生物学行为的影响及在裸鼠体内致瘤能力的改变.首先应用RT-PCR和Western 印迹检测3种不同类型造血系肿瘤细胞（K562、NB4、Jurkat T）中PTPα的表达水平.根据检测结果,选择K562细胞作为研究对象,利用脂质体将 PTPα 真核表达载体转染K562细胞,通过G418筛选获得阳性克隆,RT-PCR和Western 印迹验证过表达情况;经MTT法检测细胞增值能力的改变;用流式细胞仪检测细胞周期分布和细胞分化状态;并将阳性克隆细胞皮下接种裸鼠,观察 PTPα 基因转染前后细胞系在裸鼠体内的致瘤能力及瘤体的组织化学变化.上述实验结果表明,通过G418压力筛选获得了 PTPα 高表达多克隆细胞系K562-PTPα;经体外增殖实验分析,实验组K562-PTPα细胞与未转染组细胞K562和转染空载体组细胞K562-splice相比,细胞生长速度增快,G₂/M期细胞比例增加( P <0.05),而细胞分化状态无明显变化;裸鼠体内致瘤实验显示,K562组、K562-splice组和K562 PTPα组平均瘤重分别为(1.1±0.3)g、(1.3±0.2)g和(2.5±0.5)g;病理切片显示,K562-PTPα组瘤体组织分化程度较对照组低、恶性程度高,细胞的致瘤能力增强( P <0.01).综上所述,过表达PTPα使K562细胞具有更强的体外增殖能力和体内致瘤性,表明PTPα可能在造血系统恶性肿瘤的发生发展中发挥促进作用.     

苏云金芽胞杆菌杀虫晶体蛋白作用的分子机制研究进展

本文主要综述了苏云金芽胞杆菌（Bacillus thuringiensis,Bt）杀虫晶体蛋白在分子水平上作用机制的研究进展。杀虫晶体蛋白酶活化后形成的毒性肽一般由三个结构域组成。在杀虫过程中,毒性肽首先通过结构域Ⅱ或结构域Ⅲ的特殊部位与昆虫中肠上皮细胞膜上的受体蛋白发生专一性结合。这一结合开始是可逆的,随后发生紧密的不可逆结合。继而诱发毒性肽分子发生空间构象变化,便得结构域Ⅰ中的某些α－螺旋从α－螺旋束中弹出并插入细胞膜,并通过寡聚合作用造成膜穿孔,导致细胞渗透平衡破坏、中肠破裂、昆虫死亡。     

新型单克隆抗体(Anti-LA18)体外抗K562红白血病细胞株的观察

用细胞培养、酶细胞化学、同位素掺入等技术对新型单克隆抗体(Anti-LA18)抗K562-红白血病细胞株的作用进行了观察.结果用含不同浓度Anti-LA18抗体的培养液培养24小时后,实验组K562细胞出现体积小,核质比缩小,核染色质浓缩、胞质内空泡增多等形态学改变.酶细胞化学方法显示实验组K562细胞酸性磷酸酶、氯醋酸AS-D酯酶、酸性醋酸酯酶等反应均有所减弱,以酸性磷酸酶反应减弱最为明显.以K562细胞各种酶阳性百分率表示酶活性变化指标,对照组与实验组具有明显差异(P<0.001).抑制胸腺嘧啶核苷结合法测定Anti-LA18抗体对K562细胞增殖抑制作用,呈现纯Anti-LA18抗体浓度的依赖性.18小时~3H-TdR释放法测定Anti-LA18抗体对K562细胞的细胞毒作用,显示出杀伤活性随Anti-LA18抗体浓度的增加而增加.     

苏云金芽胞杆菌杀虫晶体蛋白作用的分子机制研究进展

本文主要综述了苏云金芽胞杆菌(Bacillusthuringiensis,Bt)杀虫晶体蛋白在分子水平上作用机制的研究进展。杀虫晶体蛋白经蛋白酶活化后形成的毒性肽一般由三个结构域组成。在杀虫过程中,毒性肽首先通过结构域Ⅱ或结构域Ⅲ的特殊部位与昆虫中肠上皮细胞膜上的受体蛋白发生专一性结合。这一结合开始是可逆的,随后发生紧密的不可逆结合。继而诱发毒性肽分子发生空间构象变化,使得结构域Ⅰ中的某些α螺旋从α螺旋束中弹出并插入细胞膜,并通过寡聚合作用造成膜穿孔,导致细胞渗透平衡破坏、中肠破裂、昆虫死亡 。     

一种源自人α-2-巨球蛋白的抗菌肽A2M3及其对金黄色葡萄球菌的抑菌机制

【目的】在人的鼻腔中鉴定出一种源自α-2-巨球蛋白的抗菌肽(命名为A2M3),并探究其对金黄色葡萄球菌(Staphylococcus aureus)的抑菌作用和机制。【方法】结合生物信息学技术对人类鼻液的质谱结果进行分析,并筛选潜在抗菌肽;通过微量稀释法和平板涂布法分别分析A2M3对金黄色葡萄球菌最低抑菌浓度(minimum inhibitory concentration, MIC)和时间杀伤曲线(time-kill curve);采用透射电镜、碘化丙锭(propidium iodide, PI)摄取实验、流式细胞术和核酸蛋白质泄露实验分析A2M3对金黄色葡萄球菌膜完整性、膜通透性的影响;通过凝胶阻滞实验和荧光光谱实验探究A2M3对金黄色葡萄球菌基因组DNA的影响。【结果】利用生物信息学技术筛选出源自α-2-巨球蛋白的潜在抗菌肽A2M3,其对金黄色葡萄球菌的MIC为125.0 μg/mL,且能在3 h内完全杀灭细菌。A2M3通过增加细胞膜的通透性,促使核酸和蛋白质泄漏,继而穿过细胞膜嵌入DNA的碱基对,影响细菌的基因功能,从而导致菌体死亡。【结论】A2M3对金黄色葡萄球菌的抑菌机制涉及多靶点协同作用,能够改变细菌细胞膜的通透性,影响细菌的基因功能。这一发现揭示了从人体体液中筛选和分离抗菌功能肽的潜在应用价值。     

下调RALA表达抑制人白血病K562细胞迁移和侵袭

目的 研究小干扰RNA（siRNA）抑制v-ral 白血病致病因子RALA基因表达对人白血病K562细胞迁移和侵袭的影响.方法 利用LipofectamineTM 2000将化学合成的RALA siRNA转染体外培养的K562细胞,Real-time PCR检测细胞内RALA mRNA的表达水平;Western印迹检测细胞内RALA蛋白的表达水平;Boyden趋化小室实验检测细胞体外迁移和侵袭能力.结果与随机对照组相比,转染48 h后,RALA siRNA显著下调K562细胞内RALA mRNA和蛋白的表达（P＜0.05）.与随机对照组相比,转染RALA siRNA的K562细胞迁移和侵袭能力显著降低（P＜0.05）.结论 癌基因RALA在人白血病K562细胞迁移和侵袭过程中发挥重要作用,通过siRNA下调RALA的表达可抑制K562细胞迁移和侵袭能力.     

冷冻干燥对乳酸菌细胞膜通透性的影响

对细胞膜通透性变化的研究是认识冷冻干燥过程对乳酸菌损伤机理的途径之一。用荧光探针检测冻干过程前后细胞内H+和Ca2+浓度的变化, 可以精确的表征细胞膜通透性的改变。利用荧光探针BCECF-AM和Fluo3-AM对德氏乳杆菌保加利亚亚种在冻干前后的细胞膜通透性进行研究, 并对比菌种在冻干过程中的活力损失, 发现细胞膜在冻干前后通透性有显著增加, 并与活力的损失成反相关关系。说明在冻干过程中细胞受到了生理性损伤, 细胞膜通透性的改变可能是导致乳酸菌在冻干过程中致死和失活的原因之一。     

RPS27a promotes proliferation,regulates cell cycle progression and inhibits apoptosis of leukemia cells

Ribosomal protein S27a (RPS27a) could perform extra-ribosomal functions besides imparting a role in ribosome biogenesis and post-translational modifications of proteins. The high expression level of RPS27a was reported in solid tumors, and we found that the expression level of RPS27a was up-regulated in advanced-phase chronic myeloid leukemia (CML) and acute leukemia (AL) patients. In this study, we explored the function of RPS27a in leukemia cells by using CML cell line K562 cells and its imatinib resistant cell line K562/G01 cells. It was observed that the expression level of RPS27a was high in K562 cells and even higher in K562/G01 cells. Further analysis revealed that RPS27a knockdown by shRNA in both K562 and K562G01 cells inhibited the cell viability, induced cell cycle arrest at S and G2/M phases and increased cell apoptosis induced by imatinib. Combination of shRNA with imatinib treatment could lead to more cleaved PARP and cleaved caspase-3 expression in RPS27a knockdown cells. Further, it was found that phospho-ERK(p-ERK) and BCL-2 were down-regulated and P21 up-regulated in RPS27a knockdown cells. In conclusion, RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells. It appears that drugs targeting RPS27a combining with tyrosine kinase inhibitor (TKI) might represent a novel therapy strategy in TKI resistant CML patients.     

Potentiation of harringtonine cytotoxicity by calcium antagonist diltiazem and biscoclaurine alkaloid cepharanthine in adriamycin-resistant P388 murine leukemia and K562 human leukemia cells

Harringtonine showed cross resistance in adriamycin-resistant murine leukemia P388 (P388/ADM) and human leukemia K562 (K562/ADM) cells. The relative resistance of the P388/ADM and K562/ADM cells to harringtonine was about 7 and 40, respectively. Calcium influx blockers, diltiazem and the biscoclaurine alkaloid cepharanthine enhanced the cytotoxicity of harringtonine in P388/ADM and K562/ADM cells. The extent of enhancement was different for the two drugs, and up to a 9- to 10-fold increase in harringtonine cytotoxicity occurred in P388/ADM cells, and 14- to 22-fold enhancement in K562/ADM cells with diltiazem or cepharanthine. Harringtonine resistance of P388/ADM was circumvented completely, and the resistance of K562/ADM was circumvented partially, by diltiazem or cepharanthine. The mechanism of enhanced cytotoxicity by diltiazem and cepharanthine is probably inhibition of active efflux of harringtonine in P388/ADM and K562/ADM cells.     

DNA甲基化通过锌指蛋白185调控慢性粒细胞白血病细胞的增殖

锌指蛋白185(ZNF185)属于LIM结构域蛋白,参与细胞的增殖和分化,在多种肿瘤细胞中具有抑癌基因的功能.ZNF185在正常人血液系统细胞中高表达,但目前对白血病细胞的作用未见研究.采用Western blot检测人外周血中性粒细胞、急性粒细胞白血病细胞系HL-60和慢性粒细胞白血病细胞系K562细胞中ZNF185的表达,发现ZNF185在HL-60和K562细胞中的表达水平显著低于外周血中性粒细胞.为了阐明ZNF185对慢性粒细胞白血病细胞增殖的影响,从人外周血中性粒细胞克隆ZNF185编码序列,转染K562细胞,MTT检测细胞增殖,发现过表达ZNF185显著抑制K562细胞的增殖.甲基化特异PCR分析表明:ZNF185启动子在HL-60和K562细胞中高甲基化,用5-氮杂-2′-脱氧胞苷处理K562细胞,促进ZNF185的表达,显著抑制细胞增殖.研究结果表明,ZNF185启动子高甲基化导致其在K562细胞中的表达降低和细胞增殖抑制作用减弱.可能是慢性粒细胞白血病发生或发展的原因之一.     

敲低去泛素化酶USP13抑制K562细胞的增殖*

目的:研究去泛素化酶USP13对人慢性髓系白血病细胞系K562增殖和凋亡的影响,并进行初步的机制探究。方法:构建pLKO.1-shUSP13-GFP慢病毒干涉载体,慢病毒包装后感染并建立稳定敲低USP13的K562细胞株。免疫印迹检测K562细胞中USP13蛋白的敲低效率。流式细胞术分析敲低USP13对K562细胞增殖和凋亡的影响。免疫共沉淀和蛋白质泛素化实验探究USP13调控K562细胞的分子机制。结果:成功构建pLKO.1-shUSP13-GFP慢病毒干涉载体,同时利用慢病毒体系获得稳定敲低USP13的K562细胞株。流式细胞术结果显示,敲低USP13促进K562细胞凋亡、抑制细胞增殖。分子机制研究发现,敲低USP13通过增强c-Myc泛素化进而导致其蛋白质水平降低。结论:初步揭示了USP13调控K562细胞增殖和凋亡的分子机制,为治疗慢性髓系白血病提供了潜在的靶点。     

Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis

In an attempt to identify novel proteins involved in the emergence of multidrug resistance (MDR) in leukemia cells, we adopted a proteomics approach to analyze protein expression patterns in leukemia cell lines, K562, and its MDR counterpart, K562/A02. Combining high-resolution two-dimensional gel electrophoresis and mass spectrometry, we compared the protein expression profiles between K562 and K562/A02. A total number of 22 protein spots with altered abundances of more than 2-fold were detected and 14 proteins were successfully identified. Consistent with our previous observations by cDNA microarray, sorcin, a 22-kDa calcium-binding protein, was also identified by this proteomic approach with a 10.4-fold up-regulation in K562/A02 cells. Overexpression of sorcin protein in K562 cells by gene transfection led to significantly reduced cytosolic calcium level and increased resistance to cell apoptosis. Further, leukemia cell lines over-expressing sorcin also showed up-regulation of Bcl-2, along with decreased level of Bax. Taken together, our results suggest that sorcin plays an important role in the emergence of MDR in leukemia cells via regulating cell apoptosis pathways, thus may represent both a new MDR marker for prognosis and a good target for anti-MDR drug development.     

Detection of 300-kilodalton membrane protein in adriamycin-resistant human tumor cells by a monoclonal antibody MRK18

To characterize the membrane changes related to adriamycin (ADM) resistance in tumor cells, we have developed monoclonal antibodies against an ADM-resistant subline of human myelogenous leukemia K562 (K562/ADM), and reported the overexpression of P-glycoprotein and 85-kDa protein as determined by the antibodies. In the present study, we have established a monoclonal antibody, MRK18, with higher reactivity to K562/ADM than to K562. MRK18 also showed higher reactivity to other human ADM-resistant lines, 2780AD and Hattori/ADM, than the corresponding parental lines. MRK18 also reacted to human breast cancer MCF-7 and human T-lymphoma CCRF-CEM which have never been exposed to anticancer agents in culture. MRK18 recognized a 300-kDa membrane protein of K562/ADM and MCF-7 and inhibited the growth of these cell lines in culture. These results indicate an induction of the 300-kDa protein during the development of ADM resistance.     

Disialoganglioside GD3 synthase expression recruits membrane transglutaminase 2 during erythroid differentiation of the human chronic myelogenous leukemia K562 cells

By employing proteomics analysis tool, we examined the effects of GD3 synthase expression on the differentiation properties of chronic myelogenous leukemia (CML)-derived leukemia cells K562. Forced expression of GD3 synthase induced erythroid differentiation as determined by an increase in glycophorin A expression and synthesis of hemoglobins. The proteomic analysis revealed that 15 proteins were increased by GD3 synthase. In contrast, we observed three protein gel spots decreased in contents in the cell membranes of GD3 synthase-transfected K562 cells. Among the increased proteins, membrane transglutaminase 2 (TG2) was specifically increased in the cell membrane of GD3 synthase-transfected K562 cells. Then, we generated the GD3 synthase-transfected cells in the K562 cells. Interestingly, the TG2 level was increased in GD3 synthase-transfected cells compared with vector- and plasma membrane-associated ganglioside sialidase (Neu3)-transfected cells. In addition, its ability to be photoaffinity-labeled with [alpha-(32)P]GTP was also increased in the GD3 synthase- and TG2-transfected cells. Moreover, small interfering RNA (siRNA) analysis for the GD3 synthase showed the decrease or abolishment of the membrane TG2. Finally, GD3 synthase-transfected cells accelerated the erythroid differentiation. Therefore, we propose that the recruitment of TG2 into membranes by GD3 might play an important role in the erythroid differentiation in K562 cells.     

The bisabolane sesquiterpenoid endoperoxide, 3,6-epidioxy-1,10-bisaboladiene, isolated from Cacalia delphiniifolia inhibits the growth of human cancer cells and induces apoptosis

In the course of our screening for a new anti-tumor substance, the bisabolane sesquiterpenoid endoperoxide, 3,6-epidioxy-1,10-bisaboladiene (EDBD), was isolated from the edible wild-plant, Cacalia delphiniifolia. EDBD showed cytotoxicity toward human chronic myelogenous leukemia K562 and human prostate carcinoma LNCaP cell lines with IC50 values of 9.1 microM and 23.4 microM, respectively. DNA fragmentation and condensation of chromatin, the hallmarks of apoptosis, appeared in K562 cells after an 18-h treatment with EDBD. alpha-Curcumene, a bisabolane sesquiterpene that lacks the endoperoxide moiety of EDBD, also showed cytotoxicity toward both K562 and LNCaP cell lines at over a 10-times higher dose than that of EDBD. The results indicate the importance of the endoperoxide structure within EDBD to its anti-tumor activity in vitro.